Active Pharmaceutical Ingredients - Dr Reddy's
Active Pharmaceutical Ingredients - Dr Reddy's

关于 Granisteron API

Product
  • CAS 编号

    109889-09-0

  • API 技术

    合成

  • 剂型

    皮下注射

  • Dr Reddy's 开发状态

    可用的

  • 可用的法规申报文件

    USDMF, 韩国 DMF, 韩国 DMF

作用机制

格拉司琼(Granisetron)是一种强效、选择性的5-HT3受体拮抗剂。其止吐作用通过抑制中枢(延髓化学感受器触发区)和外周(胃肠道)存在的5-HT3受体实现。通过抑制5-HT3受体,可阻断对呕吐中枢的内脏传入刺激——这可能在延髓后区(Area Postrema)通过间接机制发生,也可能通过直接抑制延髓后区和化学感受器触发区内的血清素活动来实现。

适应症

用于预防与致吐性癌症治疗(包括大剂量顺铂)的初始和重复疗程、术后以及放射治疗(包括全身照射和每日分次腹部放射治疗)相关的恶心和呕吐。

Dr. Reddy's的专长

Dr. Reddy's总部位于印度海得拉巴,是全球领先的活性药物成分(API)供应商之一。 Dr. Reddy's的API业务是美国、欧洲、巴西、拉丁美洲、日本、中国、韩国和新兴市场的制药公司的首选合作伙伴。

Dr. Reddy's博士的API业务在过去30多年来在开发和制造复杂API(如类固醇,多肽,复杂长链分子和高效API(HPAPI /肿瘤药物))方面所建立的深厚技术优势中茁壮成长。 我们在知识产权和法规事务方面的实力可以帮助我们始终如一地达到并超越监管标准,从而为这一专业知识提供补充。 Dr. Reddy's博士 格拉司琼 API是研发,知识产权和监管方面广泛专业知识的结果。

帮助我们的客户率先进入市场的关键组成部分是响应式供应链。 我们通过确保所有设施都高效运行并达到最新的质量,安全和生产率标准来实现这一目标。 业务和工厂之间的强大互联可以快速响应动态的市场变化,从而避免短缺并满足需求的突然激增。

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone
Country *
Select Product *
Select Regulatory Requirements
Select Purpose

Related APIs

Bortezomib(硼替佐米)

Oncology(肿瘤)

arrow

Cabazitaxel(卡巴他赛)

Oncology(肿瘤)

arrow

Cabozantinib S‑Malate(苹果酸卡博替尼)

Oncology(肿瘤)

arrow

Capecitabine(卡培他滨)

Oncology(肿瘤)

arrow

Carfilzomib(卡非佐米)

Oncology(肿瘤)

arrow

Decitabine(地西他滨)

Oncology(肿瘤)

arrow

Deucravacitinib(‌氘可来昔替尼)

Oncology(肿瘤)

arrow

Enzalutamide(恩扎卢胺)

Oncology(肿瘤)

arrow

Eribulin Mesylate(甲磺酸艾立布林)

Oncology(肿瘤)

arrow

Gemcitabine Hydrochloride(盐酸吉西他滨)

Oncology(肿瘤)

arrow

Granisetron(格拉司琼)

Oncology(肿瘤)

arrow

Midostaurin (Amorphous and Form II)(米哚妥林,无定形及 II 晶型)

Oncology(肿瘤)

arrow

Pazopanib(帕唑帕尼)

Oncology(肿瘤)

arrow

Pomalidomide(泊马度胺)

Oncology(肿瘤)

arrow

Relugolix(瑞卢戈利)

Oncology(肿瘤)

arrow

Ripretinib(瑞派替尼)

Oncology(肿瘤)

arrow

Tucatinib(图卡替尼)

Oncology(肿瘤)

arrow

Venetoclax(维奈托克)

Oncology(肿瘤)

arrow

Zoledronic Acid(唑来膦酸)

Oncology(肿瘤)

arrow

Acalabrutinib(阿卡替尼)

Oncology(肿瘤)

arrow

Adagrasib(阿达格拉西布)

Oncology(肿瘤)

arrow

Fruquintinib(呋喹替尼)

Oncology(肿瘤)

arrow

Pirtobrutinib(匹妥布替尼)

Oncology(肿瘤)

arrow

Olaparib (Form A)(奥拉帕利,A 晶型)

Oncology(肿瘤)

arrow

Palbociclib(哌柏西利)

Oncology(肿瘤)

arrow

Pemetrexed Disodium Heptahydrate(培美曲塞二钠七水合物)

Oncology(肿瘤)

arrow

Abiraterone Acetate(醋酸阿比特龙)

Oncology(肿瘤)

arrow

Apalutamide (Amorphous and Form B)(阿帕他胺,无定形及 B晶 型)

Oncology(肿瘤)

arrow

Zanubrutinib(泽布替尼)

Oncology(肿瘤)

arrow

Azacitidine(阿扎胞苷)

Oncology(肿瘤)

arrow

Nilotinib Hydrochloride(盐酸尼洛替尼)

Oncology(肿瘤)

arrow

Lenalidomide (Form A)(来那度胺,A 晶型)

Oncology(肿瘤)

arrow

Lomustine(洛莫司汀)

Oncology(肿瘤)

arrow

Lenvatinib Mesylate (Form C and MIBK Solvate)(甲磺酸仑伐替尼,C 型及 MIBK 溶合物)

Oncology(肿瘤)

arrow

Lenvatinib Mesylate (Form-C) 甲磺酸仑伐替尼(晶型 C及)

Oncology(肿瘤)

arrow

Cabozantinib Hydrochloride(盐酸卡博替尼)

Oncology(肿瘤)

arrow

Dasatinib Monohydrate(达沙替尼一水合物)

Oncology(肿瘤)

arrow

Bendamustine Hydrochloride(盐酸苯达莫司汀)

Oncology(肿瘤)

arrow

免责声明

No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.